摘要:
The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
摘要:
The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
摘要:
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. (i)
摘要:
Macrocyclic isoquinoline are disclosed having the general formula: A compound of formula 1: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
摘要:
Macrocyclic isoquinoline are disclosed having the general formula: A compound of formula 1: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
摘要:
The present invention provides (1a R ,12b S )-8-cyclohexyl-11-fluoro- N -((1- methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8- yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[ d ]indolo[2,1- a ][2]benzazepine-5- carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
摘要:
Macrocyclic peptides are disclosed having the general formula: (I) wherein R3, R'3, R4, R6, R', X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.